Navigation Links
Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Date:9/19/2007

NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 possesses several attractive properties. These include: potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R), Bristol-Myers Squibb) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral dosing regimen; limited pharmacokinetic interactions with other drugs; and the ability to be co-formulated with other HIV antiviral drugs.

About Ardea Biosciences, Inc.

Ardea Biosciences is focused on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases. The Company plans to initiate clinical studies on four compounds this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, scheduled to enter Phase 1 clinical trials in the second half of 2007, and a follow-on NNRTI and a follow-on MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including its goal of initiating a Phase 2 study of RDEA806 in HIV-infected patients and initiating clinical studies on three additional comp
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015  By looking at ... to distinguish between two very different conditions that ... Theodore Henderson , MD, PhD., a ... cases, this study can help the ... therefore treatment options, for Post-Traumatic Stress Disorder (PTSD) ...
(Date:5/4/2015)... May 4, 2015 MEI Pharma, Inc. ... on the clinical development of novel therapies for ... effects of the Company,s investigational drug candidate ME-344 ... when combined with a tyrosine-kinase inhibitor (TKI). In ... be a potent inhibitor of mitochondrial oxidative phosphorylation ...
(Date:5/4/2015)... May 4, 2015 The Pharmacy Workforce Center ... confirmed that pharmacy has shifted toward a female-dominated profession. ... and managers, there is an incredible opportunity for women ... next decade. In a new blog ... Essential Insights , Eden Sulzer, director of the ...
Breaking Medicine Technology:New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5Cardinal Health Expert Discusses Latest Research On Gender Gap In Pharmacy 2Cardinal Health Expert Discusses Latest Research On Gender Gap In Pharmacy 3
... ADDISON, Texas, March 24, 2011 ULURU Inc. (NYSE ... a conference call to discuss the fourth quarter and year ended ... Friday, April 1, 2011 at 9:00 a.m. Eastern Time. ... international callers dial (850) 429-1388 (access code 23750#) five to ten ...
... HealthCare today announced the establishment of Texas Institute for ... which will feature the Robotic Institute University, the nation,s ... surgical teams involved in robotic-assisted surgery. ... North Austin Medical Center is an international treatment, training ...
Cached Medicine Technology:ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2010 and to Provide a Business Update 2St. David's HealthCare Takes Robotic-Assisted Surgery to the Next Level With the Texas Institute for Robotic Surgery at St. David's North Austin Medical Center 2St. David's HealthCare Takes Robotic-Assisted Surgery to the Next Level With the Texas Institute for Robotic Surgery at St. David's North Austin Medical Center 3St. David's HealthCare Takes Robotic-Assisted Surgery to the Next Level With the Texas Institute for Robotic Surgery at St. David's North Austin Medical Center 4St. David's HealthCare Takes Robotic-Assisted Surgery to the Next Level With the Texas Institute for Robotic Surgery at St. David's North Austin Medical Center 5
(Date:5/4/2015)... Sheltering Arms announced that it has ... The Mother Hale Learning Center meets a tremendous need ... Sheltering Arms will begin operating the site immediately and ... the center. , Opened in 2006, the Mother Hale ... five years, many of whom come from high-need backgrounds. ...
(Date:5/4/2015)... May 04, 2015 Dr. Richard Champagne, ... been chosen to receive the America’s Best Dentist Award, ... Champagne’s selection as a top dentist is a reflection ... continuing education and his compassion for his patients. , ... who exemplify excellence in their field. These nominees are ...
(Date:5/4/2015)... Atlanta, GA (PRWEB) May 04, 2015 ... today that it has been included in the just-released ... “Being included in the Spend Matters " 50 To ... and further proof of Scanmarket’s commitment to providing comprehensive, ... Founder Ole P. Nielsen, “There are many well-established and ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 “St. Louis ... the “Gateway to the West,” so it is the ... Veterans Program”, says Dr. Ben Litalien, Chief Development Officer ... Association’s VetFran program and will provide veterans with a ... Zerorez® is proud to have a number of Military ...
(Date:5/3/2015)... 03, 2015 Women’s Excellence ... page. , Their Facebook page consists of ... the Practice has, it’s multiple locations, Providers and hospital ... has a very strong social media presence, with pages ... Tube. , Women’s Excellence is the most comprehensive ...
Breaking Medicine News(10 mins):Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Scanmarket Selected to Spend Matters "50 To Know" List of Companies in Procurement Sector. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3
... in motor vehicle crashes is closely correlated to the severity ... at the Medical College of Wisconsin in Milwaukee. ... rupture, resulting in bleeding onto the surface of the retina. ... M.D., professors of ophthalmology at the Medical College, is published ...
... for Devastating ... Neurological Disease -, HAILEY, Idaho, June 23 Charles ... on June 17, 2008, for,his support to find a cure for the ... or Parkinson,s disease. Chuck has had PSP for several years,and, despite his ...
... Pacific Corporation, one of,this country,s best kept secrets in ... as part of its current offering to existing and ... review all,financial information up to the second from their ... "We are excited to be able to offer this ...
... Findley Davies, Inc., a human,resources consulting firm, ... Association of Business Communicators (IABC) Cleveland Vision,Awards. For ... HCR,ManorCare, Findley Davies Communication Solutions practice received an,Award ... Davies Communication Solutions practice also received an Award ...
... Insurance,Company ("The Standard"), a subsidiary of StanCorp Financial ... insurance products for employers with as,few as 10 ... line, The,Standard now provides employers with the opportunity ... term disability, life, dental,and vision insurance from a ...
... patients who need little, if any, immune suppression , , ... called HLA-G dimer plays a powerful role in preventing ... Medical College of Georgia researchers say. , They ... mice and are currently studying whether this molecule is ...
Cached Medicine News:Health News:Severe retinal hemorrhaging is linked to severe motor vehicle crashes 2Health News:Advertising Hall of Famer Charles D. Peebler Receives Honor for Work Supporting Cure for Progressive Supernuclear Palsy 2Health News:Oregon Based First Pacific Corporation Launches New E-Tools Program for Dentists 2Health News:Findley Davies Receives IABC Vision Awards 2Health News:The Standard Introduces Three Flexible Vision Insurance Plans 2Health News:The Standard Introduces Three Flexible Vision Insurance Plans 3Health News:Immune Molecule Key to Preventing Organ Rejection 2
Transcranial and peripheral vascular doppler system....
One channel transcranial doppler with multigate, emboli detection, monitoring module and tests for hemodynamic evaluation. Looki 1TC is suitable as well for routine diagnosis as for monitoring in ope...
The Spencer Technologies PMD 100 (TCD 100M) is the worlds first stand-alone digital transcranial doppler system....
The portable, cost-effective system designed for fast studies and bedside reporting. The size, features and cost make this a perfect unit for a new practice, or as a second or third unit for larger h...
Medicine Products: